Abstract
We would like to make three main points in reply. First, the debate has been framed as ‘tailoring’ versus ‘no tailoring’, which is perhaps not surprising given that polypills are fixed ‑dose combination medi ‑cations. However, tailoring is possible in several ways while still allowing patients to benefit from the adherence improvements of polypills. Numerous types of polypill with different components will become available, many with variable doses of the individual component drugs. Additionally, tailoring can occur ‘on top’ of a polypill.Second, the postulated variations in treat ‑ment effect by pharmacogenetic risk score are extreme, ranging from a large treatment benefit in patients with a risk score <1 to probable harm in patients with a risk score ≥3.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
